Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 4, 2008, Pages 476-484

  Boileau, Catherine ^a   Nguyen, Vinh Kim ^b   Sylla, Mohamed ^b   MacHouf, Nima ^c   Chamberland, Annie ^b   Traoré, Hamar A ^d   Niamba, Pascal A ^e   Diallo, Ismaël ^e   Maïga, Moussa ^f   Cissé, Mamadou ^g   Rashed, Sélim ^b   Tremblay, Cécile ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Clinique Medicale l'Actuel   (Canada)

^d Hopital National du Point G   (Mali)

^e Yalgado Ouedraogo Teaching Hospital   (Burkina Faso)

^f HÔPITAL GABRIEL TOURÉ   (Mali)

^g Centre de Soins d'Animation et de Conseils Pour les Personnes Atteintes du VIH/SIDA (CESAC)   (Mali)

Author keywords

Antiretroviral treatmentmonitoring; Community based organization; Immune suppression; Public hospital; Sub Saharan Africa; Viral load

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AVOCOMB; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BURKINA FASO; CLINICAL TRIAL; COMMUNITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MALI; MEDICAL RECORD; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SELF CONCEPT; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; GENETICS; HEALTH CENTER; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PILOT STUDY; PUBLIC HOSPITAL; RISK; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; COMMUNITY HEALTH CENTERS; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS, MUNICIPAL; HUMANS; MALE; MALI; ODDS RATIO; PATIENT COMPLIANCE; PILOT PROJECTS; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 50649112427     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817dc416     Document Type: Article

References (46)

1. World Health Organization. Antiretroviral Therapy for HIV in Adults and Adolescents: Recommendations for a Public Health Approachw. WHO Press; Geneva, Switzerland. 2006:1-134.
2. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 2001;15:2379-2384.
3. Bartlett J, DeMasi R, Quinn J, et al. overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369-1377.
4. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
5. Wood E, Hogg RS, Yip B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS. 2006;20:1117-1123.
6. Skowron G, Street JC, Obee EM. Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:313-319.
7. Abgrall S, Duval X, Joly V, et al. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis. 2003;37:1517-1526.
8. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353: 863-868.
9. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr. 2000;24:218-226.
10. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224.
11. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370.
12. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther. 2003;8:385-393.
13. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS. 2003;17 (Suppl 3):S5-S15.
14. Kebba I, Atwine D, Mwebaze R, et al. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses. 2002;18:1181-1187.
15. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, et al. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16:38-41.
16. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
17. Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658-665.
18. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.
19. Walensky RP, Weinstein MC, Yazdanpanah Y, et al. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007;21:973-982.
20. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126:929-938.
21. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
22. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
23. Torre D, Tambini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials. 2002;3:1-8.
24. Jones S, Klotman ME. Impact of genotypic resistance testing on physician selection of antiretroviral therapy. J Hum Virol. 2001;4:214-216.
25. UNAIDS/WHO. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections. Mali; August 2006.
26. UNAIDS/WHO. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections. Burkina Faso: UNAIDS/WHO; Geneva, Switzerland. August 2006.
27. Nguyen VK, Grennan T, Peschard K, et al. Antiretroviral use in Ouagadougou, Burkina Faso. AIDS. 2003;17:S109-S111.
28. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav. 1997;38: 21-37.
29. Lagarde E, Congo Z, Meda N, et al. Epidemiology of HIV infection in urban Burkina Faso. Int J STD AIDS. 2004;15:395-402.
30. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
31. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10:464-470.
32. May SB, Barroso PF, Nunes EP, et al. Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil. Braz J Med Biol Res. 2007;40:551-555.
33. Robbins GK, Daniels B, Zheng H, et al. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007;1:30-37.
34. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368: 451-458.
35. Sylla M, Chamberland A, Boileau C, et al. ATARAO Group. Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF0-AG and AGK subtypes in Mali and Burkina Faso. Antivir Ther. 2008;13:141-148.
36. Dronda F, Moreno S, Moreno A, et al. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clin Infect Dis. 2002;35:1005-1009.
37. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
38. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
39. Paton NI, Sangeetha S, Earnest A, et al. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med. 2006;7:323-330.
40. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
41. Julg B, Goebel FD. Treatment interruption in HIV therapy: a SMART strategy? Infection. 2006;34:186-188.
42. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690.
43. Paasche-Orlow MK, Cheng DM, Palepu A, et al. Health literacy, antiretroviral adherence, and HIV-RNA suppression: a longitudinal perspective. J Gen Intern Med. 2006;21:835-840.
44. Weiser SD, Guzman D, Riley ED, et al. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials. 2004;5:278-287.
45. Boyd MA, Srasuebkul P, Khongphattanayothin M, et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir Ther. 2006;11:223-232.
46. Sungkanuparph S, Groger RK, Overton ET, et al. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 2006;7:437-441.